European Psychiatry - Volume 33 - March 2016

775 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S771
– the degree of antipsychotic politherapy prior to admission for the
entire sample decreased at discharge;
– at discharge, there is a difference between SDMand TaU. Antipsy-
chotic polytherapy in SDM decreases in a higher level.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1324
The utility of omega-3 fatty acids in
depression
M.A. Quintanilla ∗ alas , S. Pedrosa , L. Bosqued , C. Perez ,
B. Villagrasa , B. Aguado , P. Gracia
Lozano Blesa Hospital, Psychiatry, Zaragoza, Spain
∗ Corresponding author.
Introduction Recent studies have reported therapeutic benefit
from the use of omega-3 fatty acids (EPA and DHA) as adjunctive
treatment of depression.
Objectives The goal of this work is to assess the effectiveness
and tolerability of dietary supplementation with omega-3 in the
treatment of depressed patients.
Method Prospective, descriptive, observational study in a general
psychiatry outpatient clinic. Consecutive inclusion of depressed
patients started on dietary supplementationwith omega-3 because
of partial response to antidepressants and/or intolerance to high
doses or combination of antidepressant drugs between January
and May 2015. Sociodemographic variables, clinical data and
information about tolerability were recorded. Clinical response to
treatment over time was assessed at 4–6 months follow up using
the 5-item CGI (Clinical Global Impression) scale.
Results We included 30 depressed patients started on omega-
3. None of them reported side effects. Seventy-three percent of
patients reported clinical improvement (40% much improvement,
33% some improvement). None of them got worse. We did not find
association between clinical response and age, sex, type of depres-
sion nor duration of illness.
Conclusion Despite the limitations of this study, our work sup-
port previous positive results on the use of omega-3 fatty acids
(EPA and DHA) as adjunctive treatment of depression. Giving the
safety of its use, clinicians might recommend omega-3 as adjunc-
tive treatment of depression in cases with a partial response to
antidepressants.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1325
Antipsychotic injectable extended
release: A case report
M.D.L.C. Ramirez Dominguez ∗, L. Hernandez Gonzalez ,
I. Prieto Sánchez , A. Rodriguez Martinez , S. Fernandez Leon
Complejo Hospitalario de Huelva, Psiquiatria, Huelva, Spain
∗ Corresponding author.
Objective To demonstrate the therapeutic efficacy of aripiprazole
LP by a case of difficult clinical management and that we often find
in our daily practice.
Methods Description of a clinical case of a 21-year-old man,
recently diagnosed with paranoid schizophrenia with no aware-
ness of disease neither treatment adherence and harmful use of THC
and cocaine that are identified as precipitating factors for multiple
hospital admissions.
Results Injectable medication with objective clinical improve-
ment is significant, cessation of readmissions, achieving improve-
ment in all parameters measured functionality and proper
adherence to treatment as well as outpatient mental health of both
devices as of drug dependence.
Conclusion Psychiatry is facing the great challenge of modifying
the natural history to the deterioration of schizophrenia, a disease
considered one of the leading causes of years lived with disability.
The objectives medium and long-term treatment of this disease
are centered on the delay-avoidance disability and improving the
functioning and quality of life of people with this disease.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1326
Adherence to treatment and number
of relapses in patients treated with
atypical antipsychotic prolonged
release
M.D.L.C. Ramirez Dominguez ∗, I. Prieto Sánchez , M. Nu˜nez Caro ,
N. Garrido Torres , A.S. Biedma Martn
Complejo Hospitalario de Huelva, Psiquiatria, Huelva, Spain
∗ Corresponding author.
Introduction The extended release injectable offers a good alter-
native for those patients with no or poor adherence to treatment.
Numerous studies indicate that decrease the number of relapses
in such individuals. Our aim is to check whether a group of our
patients diagnosed with dual pathology coincide with these data.
Methods We followed a group of 5 patients diagnosed with para-
noid schizophrenia or delusional disorder with drug consumption
in the last year. We measured the number of relapses, understood
as the number of visits to emergency and outpatient devicesMental
Health Hospitals and hospitalizations six months before the start
of treatment with aripiprazole injectable extended release and six
months after.
Results The preliminary results point to a significant reduction
in the number of emergency room visits and hospitalizations after
starting sustained release injectable treatment.
Conclusions Our preliminary results are consistent with the lit-
erature, we found also reduced consumption of toxic and better
adherence to drug addiction devices. The new antipsychotics
extended release is a good alternative for patients with dual diag-
nosis.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1327
Electroconvulsive therapy: Brief
versus ultrabrief pulse right unilateral
electroconvulsive therapy
M.R. Raposo ∗, M.L. Medina , A.L. González , I. Martínez ,
A. Gil , A. Belmar , M.D. Piqueras , J.B. Murcia , V. Ivanov ,
P. Manzur , A. Busaileh
1 Servicio Murciano de Salud, Centro de Salud Mental Cartagena,
Hospital Universitario Santa Lucía, Cartagena, Murcia, Spain
2 Servicio Murciano de Salud, Unidad de Corta Estancia, Hospital
Román Alberca, Murcia, Spain
3 Servicio Murciano de Salud, Residencia Psicogeriátrica Virgen del
Valle, El Palmar, Murcia, Spain
4 Servicio Murciano de Salud, Unidad Regional de Media Estancia,
Hospital Psiquiátrico Román Alberca, Murcia, Spain
5 Servicio Murciano de Salud, Centro de Salud Mental Cartagena,
Hospital Universitario Santa Lucía, Cartagena, Murcia, Spain
6 Servicio Murciano de Salud, Hospital Universitario Santa Lucía,
Cartagena, Murcia, Spain
7 Servicio Murciano de Salud, Centro de Salud Mental Cartagena,
Cartagena, Murcia, Spain